<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14088">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00334633</url>
  </required_header>
  <id_info>
    <org_study_id>F040329003</org_study_id>
    <secondary_id>R01AI058033</secondary_id>
    <nct_id>NCT00334633</nct_id>
  </id_info>
  <brief_title>Treatment of Bacterial Vaginosis (BV) With Tinidazole</brief_title>
  <official_title>Tinidazole for the Treatment of Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are trying to determine if treatment of bacterial vaginosis with tinidazole is better
      than treatment with metronidazole
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bacterial vaginosis (BV) is the most prevalent cause of symptomatic vaginal discharge in the
      U.S. and has been associated with complications including preterm delivery of infants,
      pelvic inflammatory disease (PID), urinary tract infections (UTI) and
      acquisition/transmission of sexually transmitted diseases (STDs) including human
      immunodeficiency virus (HIV). Control of BV has been advocated as a means of decreasing the
      prevalence of these complications. However, the etiology of BV remains unknown and the
      current treatment regimens are inadequate in terms of initial cure and recurrence rates.
      Although not currently licensed in the U.S., tinidazole is an antimicrobial related to
      metronidazole which has shown promise for the treatment of BV in European studies and is
      widely used worldwide for the treatment of trichomoniasis including infections which are
      resistant to metronidazole. We hypothesize that qualities of tinidazole such as its longer
      half-life and its seemingly superior side effect profile as compared to oral metronidazole
      will result in its being a more efficacious drug for the treatment of BV than the currently
      available options.

      The specific aims of this project are:

        1. To compare the efficacy of two different doses of tinidazole with oral metronidazole
           for the initial treatment of symptomatic BV as well as short-term recurrence rates

        2. To compare the side effect profiles of tinidazole versus metronidazole in the treatment
           of BV

        3. To compare drug levels of tinidazole and metronidazole in the vaginal secretions and
           correlate with microbiologic cure of BV as well as rates of recurrence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cure of Bacterial Vaginosis</measure>
    <time_frame>one month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of BV</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">593</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metronidazole 500 BID for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tinidazole 500</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tinidazole 500 BID for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tinidazole 1 gm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tinidazole 1 gm BID for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tinidazole, metronidazole</intervention_name>
    <description>Tinidazole 500 mg bid; Tinidazole 1mg bid; Metronidazole 500mg bid</description>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>tinidazole 500</arm_group_label>
    <arm_group_label>tinidazole 1 gm</arm_group_label>
    <other_name>Tindamax, Flagyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women be at least 18 years of age

          -  Have symptoms of vaginal odor and or/discharge

          -  Meet the clinical (Amsel) criteria for BV

          -  Willing to participate in research

        Exclusion Criteria:

          -  Presence of another vaginal infection or STD

          -  Allergy to metronidazole

          -  Pregnant or nursing

          -  Use of oral or intravaginal antibiotics within the past 2 weeks

          -  HIV or other chronic disease

          -  Inability to keep return appointments
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Schwebke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jefferson County Department of Health STD Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>May 24, 2011</lastchanged_date>
  <firstreceived_date>June 7, 2006</firstreceived_date>
  <firstreceived_results_date>March 3, 2011</firstreceived_results_date>
  <responsible_party>
    <name_title>Jane Schwebke , MD</name_title>
    <organization>University of Alabama at Birmingham</organization>
  </responsible_party>
  <keyword>bacterial vaginosis</keyword>
  <keyword>tinidazole</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Tinidazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>women attending an STD clinic with symptomatic BV</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Metronidazole</title>
          <description>metronidazole 500 BID for 7 days; 197 participants</description>
        </group>
        <group group_id="P2">
          <title>Tinidazole 500 mg</title>
          <description>tinidazole 500 BID for 7 days; 200 particpants</description>
        </group>
        <group group_id="P3">
          <title>Tinidazole 1 gm</title>
          <description>tinidazole 1 gm BID for 7 days; 196 particpants</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="197"/>
                <participants group_id="P2" count="200"/>
                <participants group_id="P3" count="196"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="118"/>
                <participants group_id="P3" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="82"/>
                <participants group_id="P3" count="82"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metronidazole</title>
          <description>metronidazole 500 BID for 7 days; 197 participants</description>
        </group>
        <group group_id="B2">
          <title>Tinidazole 500 mg</title>
          <description>tinidazole 500 BID for 7 days; 200 particpants</description>
        </group>
        <group group_id="B3">
          <title>Tinidazole 1 gm</title>
          <description>tinidazole 1 gm BID for 7 days; 196 particpants</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="197"/>
                <measurement group_id="B2" value="200"/>
                <measurement group_id="B3" value="196"/>
                <measurement group_id="B4" value="593"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="197"/>
                <measurement group_id="B2" value="200"/>
                <measurement group_id="B3" value="196"/>
                <measurement group_id="B4" value="593"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="28" spread="6.2"/>
                <measurement group_id="B2" value="28.3" spread="6.6"/>
                <measurement group_id="B3" value="28.5" spread="6.8"/>
                <measurement group_id="B4" value="28.3" spread="6.7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="197"/>
                <measurement group_id="B2" value="200"/>
                <measurement group_id="B3" value="196"/>
                <measurement group_id="B4" value="593"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="197"/>
                <measurement group_id="B2" value="200"/>
                <measurement group_id="B3" value="196"/>
                <measurement group_id="B4" value="593"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cure of Bacterial Vaginosis</title>
        <time_frame>one month</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Metronidazole</title>
            <description>metronidazole 500 BID for 7 days; 197 participants</description>
          </group>
          <group group_id="O2">
            <title>Tinidazole 500 mg</title>
            <description>tinidazole 500 BID for 7 days; 200 particpants</description>
          </group>
          <group group_id="O3">
            <title>Tinidazole 1 gm</title>
            <description>tinidazole 1 gm BID for 7 days; 196 particpants</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="117"/>
                  <measurement group_id="O2" value="118"/>
                  <measurement group_id="O3" value="114"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cure of Bacterial Vaginosis</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                  <measurement group_id="O2" value="73"/>
                  <measurement group_id="O3" value="77"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrence of BV</title>
        <time_frame>12 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metronidazole</title>
          <description>metronidazole 500 BID for 7 days; 197 participants</description>
        </group>
        <group group_id="E2">
          <title>Tinidazole 500 mg</title>
          <description>tinidazole 500 BID for 7 days; 200 particpants</description>
        </group>
        <group group_id="E3">
          <title>Tinidazole 1 gm</title>
          <description>tinidazole 1 gm BID for 7 days; 196 particpants</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="197"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="197"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="200"/>
                <counts group_id="E3" subjects_affected="145" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="126"/>
                <counts group_id="E2" events="54" subjects_affected="54" subjects_at_risk="161"/>
                <counts group_id="E3" events="91" subjects_affected="91" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>vaginal candidiasis</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="126"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="161"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="126"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="161"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>jane R Schwebke, MD</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-975-5665</phone>
      <email>schwebke@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
